{{Medical}}
{{Infobox disease
| Name           = 鎮痛劑腎病<br>({{lang|en|Analgesic nephropathy}})
| Image          = Phenacetin skeletal.svg
| Caption        = 傳統上為含有[[非那西丁|非那西丁]](上圖)混合鎮痛藥所引起的，鎮痛劑腎病一度為[[急性腎損傷|急性腎損傷]](AKI)最常見的原因。
| DiseasesDB     = 
| ICD10          = {{ICD10|N|14|0|n|10}}
| ICD9           = {{ICD9|583.89}}, {{ICD9|584.7}}
| ICDO           = 
| OMIM           = 
| MedlinePlus    = 000482
| eMedicineSubj  = med
| eMedicineTopic = 2839
| MeshID         = 
}}

'''鎮痛劑腎病'''({{lang|en|Analgesic nephropathy}})是由[[镇痛药|镇痛药]]，比如[[阿司匹林|阿司匹林]]、[[非那西汀|非那西汀]]、[[对乙酰氨基酚|对乙酰氨基酚]]等所誘發的腎臟損傷疾病。鎮痛劑腎病這個詞語通常是指來自於過度使用這些鎮痛藥物的組合，特別是包括非那西丁的藥物組合。它也可以被用於描述來自於任何單一鎮痛藥物所引起的腎臟損傷。

由鎮痛藥所誘發的特異性腎損傷為[[腎乳頭壞死|腎乳頭壞死]]及[[間質性腎炎|慢性間質性腎炎]]。它們出現[[腎血流量|腎血流量]](renal blood flow)的減少、[[抗氧化剂|抗氧化剂]]的快速消耗，以及隨後的[[氧化应激|氧化損傷]]腎臟的結果等現象。腎損害可能導致進行性的[[慢性肾脏病|慢性腎功能衰竭]]、異常[[尿液分析|尿液分析]]現象、[[高血壓|高血壓]]，及[[貧血|貧血]]。一小部分具有鎮痛劑腎病的病患可能發展為[[慢性肾脏病|終末期腎病]]。

鎮痛劑腎病一度在[[歐洲|歐洲]]，[[澳大利亞|澳大利亞]]及[[美國|美國]]的部分地區為腎損傷及終末期腎臟病最常見的病症。在大多數地區、其發病率急劇下降，因為在20世紀70年代和80年代使用非那西丁的下降故。

==歷史==
{{main|非那西丁|镇痛药}}

[[镇痛药|镇痛药]]是一類廣泛應用於治療疼痛的藥物。它們包括[[阿司匹林|阿司匹林]]及和其他[[非甾体抗炎药|非甾体抗炎药]](NSAIDs)，以及[[退燒藥|退燒藥]](Antipyretic)[[对乙酰氨基酚|撲熱息痛]](在美國稱為[[对乙酰氨基酚|acetaminophen]])與[[非那西丁|非那西丁]]。在19世紀後期推出，在歐洲，澳大利亞和美國的部分地區非那西丁一度混合鎮痛藥為[[複方藥|複方藥]](Combination drug)。<ref name="pmid9734593">{{cite journal |author=McLaughlin JK, Lipworth L, Chow WH, Blot WJ |title=Analgesic use and chronic renal failure: a critical review of the epidemiologic literature |journal=Kidney Int. |volume=54 |issue=3 |pages=679–86 |date=September 1998 |pmid=9734593 |doi=10.1046/j.1523-1755.1998.00043.x}}</ref>這些組合的鎮痛藥含有阿司匹林，或其他藥物、如NSAID與非那西丁、撲熱息痛或水楊酰胺，以及咖啡因或[[可待因|可待因]]所組成。<ref name="an-utd">{{cite book |last=de Broe |first=Marc E |editor=Curhan, Gary C (ed.) |title=UpToDate |accessdate=2008-09-30 |year=2008 |location=Waltham, MA |chapter=Analgesic nephropathy}}</ref>
<!--
In the 1950s, Spühler and Zollinger reported an association between kidney injury and the chronic use of phenacetin.<ref name="pmid13137299">{{cite journal |author=Spühler O, Zollinger HU |title=Die chronisch-interstitielle Nephritis. |language=German |journal=Z Klin Med |volume=151 |issue=1 |pages=1–50 |year=1953 |pmid=13137299 |doi= |url=}}</ref> They noted that chronic users of phenacetin had an increased risk of developing specific kidney injuries, namely [[renal_papillary_necrosis|renal papillary necrosis]] and [[interstitial_nephritis|chronic interstitial nephritis]]. This condition was dubbed analgesic nephropathy and was attributed to phenacetin, although no absolute causative role was demonstrated. With further reports of the increased risk of kidney injury with prolonged and excessive phenacetin use, however, phenacetin was banned in several countries between the 1960s and 1980s.<ref name="pmid9734593"/>

As the use of phenacetin declined, so too did the prevalence of analgesic nephropathy as a cause of end-stage renal disease. Data from [[Switzerland|Switzerland]], for example, demonstrated a decline in the prevalence of analgesic nephropathy among people with end-stage renal disease, from 28% in 1981 to 12% in 1990.<ref name="pmid7816247">{{cite journal |author=Brunner FP, Selwood NH |title=End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee |journal=Nephrol. Dial. Transplant. |volume=9 |issue=10 |pages=1371–6 |year=1994 |pmid=7816247 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7816247}}</ref> An autopsy study performed in Switzerland suggested that the prevalence of analgesic nephropathy in the general population has likewise decreased; the prevalence was 3% in 1980 and 0.2% in 2000.<ref name="pmid16891638"/>

While these data demonstrate that analgesic nephropathy has been all but eliminated in some regions, in other regions the condition persists. Notably, in Belgium, the prevalence of analgesic nephropathy among people having dialysis was 17.9% in 1984 and 15.6% in 1990.<ref name="pmid8177475">{{cite journal |author=Elseviers MM, de Broe ME |title=Analgesic nephropathy in Belgium is related to the sales of particular analgesic mixtures |journal=Nephrol. Dial. Transplant. |volume=9 |issue=1 |pages=41–6 |year=1994 |pmid=8177475 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=8177475}}</ref><ref name="pmid7753450">{{cite journal |author=Noels LM, Elseviers MM, de Broe ME |title=Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium |journal=Nephrol. Dial. Transplant. |volume=10 |issue=2 |pages=167–74 |year=1995 |pmid=7753450 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7753450}}</ref> Michielsen and de Schepper suggest that analgesic nephropathy persists among people in Belgian having dialysis not due to non-phenacetin analgesics, but because Belgium accepts a higher proportion of elderly people for dialysis. According to these authors, a greater proportion have analgesic nephropathy because a greater percentage of people in Belgian having dialysis have been exposed to long-term use of phenacetin.<ref name="pmid11181803">{{cite journal |author=Michielsen P, de Schepper P |title=Trends of analgesic nephropathy in two high-endemic regions with different legislation |journal=J. Am. Soc. Nephrol. |volume=12 |issue=3 |pages=550–6 |date=March 2001 |pmid=11181803 |doi= |url=http://jasn.asnjournals.org/cgi/pmidlookup?view=long&pmid=11181803}}</ref>-->

== 病理生理學==
{{seealso|腎功能|腎生理學}}
<!--
The scarring of the small blood vessels, called capillary sclerosis, is the initial lesion of analgesic nephropathy.<ref name="pmid6641031">{{cite journal |author=Mihatsch MJ, Hofer HO, Gudat F, Knüsli C, Torhorst J, Zollinger HU |title=Capillary sclerosis of the urinary tract and analgesic nephropathy |journal=Clin. Nephrol. |volume=20 |issue=6 |pages=285–301 |date=December 1983 |pmid=6641031 |doi= |url=}}</ref> Found in the [[renal_pelvis|renal pelvis]], [[ureter|ureter]], and capillaries supplying the [[nephron|nephron]]s, capillary sclerosis is thought to lead to [[renal_papillary_necrosis|renal papillary necrosis]] and, in turn, [[interstitial_nephritis|chronic interstitial nephritis]].<ref name="pmid16891638">{{cite journal |author=Mihatsch MJ, Khanlari B, Brunner FP |title=Obituary to analgesic nephropathy--an autopsy study |journal=Nephrol. Dial. Transplant. |volume=21 |issue=11 |pages=3139–45 |date=November 2006 |pmid=16891638 |doi=10.1093/ndt/gfl390 |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=16891638}}</ref><ref name="pmid6641031"/>

How phenacetin and other analgesics lead to this damage is incompletely understood. It is currently thought that the renal toxicities of NSAIDs and the antipyretics phenacetin and paracetamol may combine to give rise to analgesic nephropathy. A committee of investigators reported in 2000 that there was insufficient evidence to suggest that non-phenacetin analgesics by themselves are associated with analgesic nephropathy.<ref name="pmid11115060">{{cite journal |author=Feinstein AR, Heinemann LA, Curhan GC, ''et al.'' |title=Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy |journal=Kidney Int. |volume=58 |issue=6 |pages=2259–64 |date=December 2000 |pmid=11115060 |doi=10.1046/j.1523-1755.2000.00410.x}}</ref>-->

=== 阿司匹林與NSAIDs===
<!--
Proper [[Renal_function|kidney function]] depends upon adequate blood flow to the kidney. [[Renal_blood_flow|Kidney blood flow]] is a complex, tightly regulated process that relies on a number of [[hormone|hormone]]s and other small molecules, such as [[prostaglandin|prostaglandin]]s. Under normal circumstances, [[prostaglandin_E2|prostaglandin E2]] (PGE<sub>2</sub>) produced by the kidney is necessary to support adequate blood flow to the kidney. Like all prostaglandins, PGE<sub>2</sub> synthesis depends upon the [[cyclooxygenase|cyclooxygenase]]s.

Aspirin and other NSAIDs are inhibitors of the cyclooxygenases. In the kidney, this inhibition results in decreased PGE<sub>2</sub> concentration causing a reduction in blood flow. Because blood flow to the kidney first reaches the [[renal_cortex|renal cortex]] (outside) and then the [[renal_medulla|renal medulla]] (inside), the deeper structures of the kidney are most sensitive to decreased blood flow. Thus the innermost structures of the kidney, called the [[renal_papilla|renal papilla]]e, are especially dependent on prostaglandin synthesis to maintain adequate blood flow. Inhibition of cyclooxygenases therefore rather selectively damages the renal papillae, increasing the risk of [[renal_papillary_necrosis|renal papillary necrosis]].<ref name="an-utd"/>

Most healthy kidneys contain enough physiologic reserve to compensate for this NSAID-induced decrease in blood flow. However, those subjected to additional injury from phenacetin or paracetamol may progress to analgesic nephropathy.-->

=== 非那西汀與撲熱息痛===
<!--
It is unclear how phenacetin induces injury to the kidney.<ref name="an-utd"/> Bach and Hardy have proposed that phenacetin's metabolites lead to [[lipid_peroxidation|lipid peroxidation]] that damages cells of the kidney.<ref name="pmid3910912">{{cite journal |author=Bach PH, Hardy TL |title=Relevance of animal models to analgesic-associated renal papillary necrosis in humans |journal=Kidney Int. |volume=28 |issue=4 |pages=605–13 |date=October 1985 |pmid=3910912 |doi= 10.1038/ki.1985.172|url=}}</ref>

[[Paracetamol|Paracetamol]] is the major metabolite of phenacetin and may contribute to kidney injury through a specific mechanism. In cells of the kidney, cyclooxygenases catalyse the conversion of paracetamol into [[NAPQI|''N''-acetyl-''p''-benzoquinoneimine]] (NAPQI).<ref name="pmid6798713">{{cite journal |author=Mohandas J, Duggin GG, Horvath JS, Tiller DJ |title=Metabolic oxidation of acetaminophen (paracetamol) mediated by cytochrome P-450 mixed-function oxidase and prostaglandin endoperoxide synthetase in rabbit kidney |journal=Toxicol. Appl. Pharmacol. |volume=61 |issue=2 |pages=252–9 |date=November 1981 |pmid=6798713 |doi= 10.1016/0041-008X(81)90415-4|url=http://linkinghub.elsevier.com/retrieve/pii/0041-008X(81)90415-4}}</ref> NAPQI depletes glutathione via non-enzymatic conjugation to [[glutathione|glutathione]], a naturally occurring [[antioxidant|antioxidant]].<ref name="pmid8669429">{{cite journal |author=Duggin GG |title=Combination analgesic-induced kidney disease: the Australian experience |journal=Am. J. Kidney Dis. |volume=28 |issue=1 Suppl 1 |pages=S39–47 |date=July 1996 |pmid=8669429 |doi= 10.1016/S0272-6386(96)90568-5|url=}}</ref> With depletion of glutathione, cells of the kidney become particularly sensitive to [[oxidative_stress|oxidative damage]].-->

== 臨床特點==
<!--
{| class="wikitable" style="float:right; margin:10px"
|+ Clinical findings in analgesic nephropathy<ref name="pmid713270"/>
|-
! Finding
! Proportion affected
|-
| Headache
| 35-100%
|-
| Pyuria
| 50-100%
|-
| Anemia
| 60-90%
|-
| Hypertension
| 15-70%
|-
| Gastrointestinal symptoms
| 40-60%
|-
| Urinary tract infection
| 30-60%
|}

Common findings in people with analgesic nephropathy include [[headache|headache]], [[anemia|anemia]], high blood pressure ([[hypertension|hypertension]]), and white blood cells in the urine ([[pyuria|pyuria]]).<ref name="pmid713270">{{cite journal |author=Murray TG, Goldberg M |title=Analgesic-associated nephropathy in the U.S.A.: epidemiologic, clinical and pathogenetic features |journal=Kidney Int. |volume=13 |issue=1 |pages=64–71 |date=January 1978 |pmid=713270 |doi= 10.1038/ki.1978.9|url=}}</ref> Some individuals with analgesic nephropathy may also have protein in their urine ([[proteinuria|proteinuria]]).<ref name="pmid362034">{{cite journal |author=Nanra RS, Stuart-Taylor J, de Leon AH, White KH |title=Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia |journal=Kidney Int. |volume=13 |issue=1 |pages=79–92 |date=January 1978 |pmid=362034 |doi= 10.1038/ki.1978.11|url=}}</ref>-->

== 診斷==

==倂發症==
鎮痛藥腎病的併並發症包括[[腎盂腎炎|腎盂腎炎]](pyelonephritis)<ref name="pmid10620560">{{cite journal |author=Maisonneuve P, Agodoa L, Gellert R, ''et al.'' |title=Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study |journal=Am. J. Kidney Dis. |volume=35 |issue=1 |pages=157–65 |date=January 2000 |pmid=10620560 |doi= 10.1016/S0272-6386(00)70316-7|url=http://linkinghub.elsevier.com/retrieve/pii/S0272638600765127}}</ref> 及[[慢性肾脏病|終末期腎病]]。<ref name="pmid7816247">{{cite journal |author=Brunner FP, Selwood NH |title=End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee |journal=Nephrol. Dial. Transplant. |volume=9 |issue=10 |pages=1371–6 |year=1994 |pmid=7816247 |doi= |url=http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7816247}}</ref><!--Risk factors for poor prognosis include recurrent urinary tract infection and persistently elevated blood pressure.<ref name="pmid4638849"/> Analgesic nephropathy also appears to increase the risk of developing cancers of the [[urinary_system|urinary system]].<ref name="pmid7045494">{{cite journal |author=Blohmé I, Johansson S |title=Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy |journal=Kidney Int. |volume=20 |issue=5 |pages=671–5 |date=November 1981 |pmid=7045494 |doi= 10.1038/ki.1981.192|url=}}</ref>-->















常指的是被誘導過度使用一些複合藥物的所造成的傷害，尤其是那些包括[[非那西丁|非那西丁]]的複合藥物 use of combinations of these medications, specifically combinations that include phenacetin. For this reason, it is also called '''analgesic abuse nephropathy'''. Murray prefers the less judgmental '''analgesic-associated nephropathy'''.<ref name="pmid713270"/> Both terms are abbreviated to the acronym '''AAN''', by which the condition is also commonly known.-->

==註釋==
{{reflist|2}}

{{Nephrology}}

[[Category:肾脏疾病|Category:肾脏疾病]]